Blood flow modification in the SCCVII tumor: effects of 5-hydroxytryptamine, hydralazine, and propranolol.
The effects of hydralazine, 5-hydroxytryptamine (5-HT), and propranolol on blood flow in the SCCVII tumor were assessed using laser Doppler flowmetry. Both hydralazine and 5-HT, at doses of 1 and 5 mg/kg, reduced blood flow, as did propranolol at 10 mg/kg. Hydralazine and 5-HT at doses of 0.25 mg/kg slightly increased tumor blood flow, and a 10-20% increase in blood flow was also observed after 1 mg/kg of propranolol. However, propranolol at 1 mg/kg enhanced the blood flow reduction observed with 1 mg/kg of hydralazine. The concomitant administration of hydralazine and propranolol at these doses also translated into increased potentiation of the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069.
Peters
C E
CE
Medical Biophysics Unit, B.C. Cancer Research Centre, Vancouver, Canada.
Chaplin
D J
DJ
D000818:Animals; D001783:Blood Flow Velocity / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004912:Erythrocytes / Q000187:drug effects / Q000502:physiology; D006830:Hydralazine / Q000008:administration & dosage / Q000494:pharmacology*; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D051379:Mice; D008809:Mice, Inbred C3H; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000098:blood supply* / Q000503:physiopathology; D011433:Propranolol / Q000008:administration & dosage / Q000494:pharmacology*; D012701:Serotonin / Q000008:administration & dosage / Q000494:pharmacology*
D006830:Hydralazine; D012701:Serotonin; D011433:Propranolol